Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA35936
Max Phase: Preclinical
Molecular Formula: C22H23N5O6
Molecular Weight: 453.46
Molecule Type: Small molecule
Associated Items:
ID: ALA35936
Max Phase: Preclinical
Molecular Formula: C22H23N5O6
Molecular Weight: 453.46
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1c(NCc2ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc2)ccc2nc(N)nc(O)c12
Standard InChI: InChI=1S/C22H23N5O6/c1-11-14(6-7-15-18(11)20(31)27-22(23)26-15)24-10-12-2-4-13(5-3-12)19(30)25-16(21(32)33)8-9-17(28)29/h2-7,16,24H,8-10H2,1H3,(H,25,30)(H,28,29)(H,32,33)(H3,23,26,27,31)
Standard InChI Key: PWDUHBWWDCSSPY-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 453.46 | Molecular Weight (Monoisotopic): 453.1648 | AlogP: 1.89 | #Rotatable Bonds: 9 |
Polar Surface Area: 187.76 | Molecular Species: ACID | HBA: 8 | HBD: 6 |
#RO5 Violations: 1 | HBA (Lipinski): 11 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 3.29 | CX Basic pKa: 2.67 | CX LogP: 1.54 | CX LogD: -4.53 |
Aromatic Rings: 3 | Heavy Atoms: 33 | QED Weighted: 0.28 | Np Likeness Score: -0.55 |
1. Hynes JB, Kumar A, Tomazic A, Washtien WL.. (1987) Synthesis of 5-chloro-5,8-dideaza analogues of folic acid and aminopterin targeted for colon adenocarcinoma., 30 (8): [PMID:3612694] [10.1021/jm00391a042] |
2. Hynes JB, Yang YC, McGill JE, Harmon SJ, Washtien WL.. (1984) Improved synthesis and antitumor evaluation of 5,8-dideazaisofolic acid and closely related analogues., 27 (2): [PMID:6694171] [10.1021/jm00368a023] |
3. Hynes JB, Patil SA, Tomazic A, Kumar A, Pathak A, Tan XH, Li XQ, Ratnam M, Delcamp TJ, Freisheim JH.. (1988) Inhibition of murine thymidylate synthase and human dihydrofolate reductase by 5,8-dideaza analogues of folic acid and aminopterin., 31 (2): [PMID:3339615] [10.1021/jm00397a031] |
4. Chen BK, Horváth C, Bertino JR.. (1979) Multivariate analysis and quantitative structure-activity relationships. Inhibition of dihydrofolate reductase and thymidylate synthetase by quinazolines., 22 (5): [PMID:110930] [10.1021/jm00191a005] |
Source(1):